Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 9.

Journal Article

Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Freeman, C. L., Dixon, M., Houghton, R., Kreuzer, K-A, Fingerle-Rowson, G., Herling, M., Humphrey, K., Boettcher, S., de Costa, C. S., Iglesias, V., Stilgenbauer, S., Gribben, J., Hallek, M. and Goede, V. (2016). Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia, 30 (8). S. 1763 - 1768. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., Dela Serna, J., Dilhuydy, M. S., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Langerak, A. W., Ritgen, M., Stilgenbauer, S., Doehner, H., Asikanius, E., Humphrey, K., Wenger, M. K. and Hallek, M. (2014). Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial. Br. J. Haematol., 165. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., Fingerle-Rowson, G. and Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29 (7). S. 1602 - 1606. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Humerickhouse, R., Punnoose, E. A., Li, Y., Boyer, M., Humphrey, K., Mobasher, M. and Kater, A. P. (2018). Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med., 378 (12). S. 1107 - 1121. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Terszowski, G., Crompton, N., Goede, V., Humphrey, K., Lei, G., Klein, C., Mundt, K. and Stern, M. (2016). ASSOCIATION BETWEEN KIR/HLA GENOTYPE AND OUTCOME IN THE CLL11 STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS RECEIVING CHLORAMBUCIL ALONE OR IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB. Haematologica, 101. S. 54 - 56. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

This list was generated on Thu Mar 28 17:19:46 2024 CET.